After hysterectomy, progesterone is usually not needed solely for protection of the uterine lining during estrogen treatment. An endometriosis history or uncertainty about residual tissue can change the discussion. Conflicting advice may reflect different operations or a prescription intended for another purpose, rather than a single rule that applies to everyone.

Begin with what was removed, why surgery was performed and what the current hormone treatment is meant to achieve. Those details help a clinician explain whether the usual approach applies or whether there is a relevant exception. This article provides questions to clarify the record, not a yes-or-no instruction to add, continue or stop progesterone.

Editorial illustration: two consultation chairs and a notebook on a side table.
Progesterone after hysterectomy: which details change the conversation — bring the unanswered questions into the appropriate professional conversation.

Do you need progesterone after hysterectomy?

After the uterus has been removed, estrogen alone is often an option because there is no intact uterine lining requiring the usual protective progestogen component. However, the Femring label, for example, notes that some people with a hysterectomy and an endometriosis history may still need a progestin. A general statement about hysterectomy is therefore not a complete clinical assessment.

Ask why progesterone is being discussed in your case and whether the reason concerns residual tissue, another condition or a different treatment goal. Our systemic-estrogen guide explains the ordinary protective role. Knowing that role helps you ask for the exception to be explained without assuming that either the existing prescription or the general advice must be wrong.

Editorial illustration: an unbranded container, information sheet and magnifying glass.
The usual approach and its limits belong in the same sentence — keep the exact product identity and its complete label together.

What do total, partial and supracervical hysterectomy mean?

ACOG's hysterectomy guidance distinguishes removal of the uterus and cervix from a supracervical procedure, in which the cervix remains. The ovaries and tubes may be removed or retained separately. Everyday descriptions such as partial or everything removed may not communicate those distinctions accurately enough for a prescribing decision.

If you are unsure, ask the care team to obtain the operative or relevant pathology report. Tell them what you remember without trying to reconstruct missing details. A medicine list may identify current treatment but not the anatomy or reason behind the operation. The aim is to resolve the uncertainty through the clinical record, not ask you to interpret a surgical report independently.

What uncertainty remains after subtotal hysterectomy?

The UK BMS protection guidance (May 2026 file; reviewed February 2026) describes limited evidence concerning progestogen needs after subtotal hysterectomy, including concern about residual endometrial tissue. That is a narrower question than whether a cervix is present. It requires clinical interpretation of the operation and subsequent history rather than an assumption from the procedure's shorthand name.

Bring any bleeding history to that discussion, including episodes that occurred long after surgery. This guide does not reproduce a hormone challenge, cycle or trial-and-error regimen to determine whether tissue remains. Ask what is known from the records and whether further assessment is needed. The uncertainty should be made explicit before a prescriber explains the rationale for the chosen hormone plan.

Editorial illustration: an unbranded container, information sheet and magnifying glass.
Subtotal surgery can leave an additional uncertainty — keep the exact product identity and its complete label together.

A history of endometriosis deserves its own discussion

Endometriosis involves tissue resembling the uterine lining outside the uterine cavity. Removing the uterus does not necessarily establish that all relevant disease was removed. The British Menopause Society's February 2026 guidance discusses why residual disease can affect hormone choices after hysterectomy and emphasizes the limited high-quality evidence available to quantify some risks.

Ask the clinician how the original disease, surgery findings, symptoms and other risk factors affect the proposed treatment. This is not a recommendation for a particular combination or an estimate of your recurrence risk. It is a reason to avoid treating all hysterectomies as equivalent. Where the history is complex, ask whether the clinician managing menopause care needs input from the team familiar with the endometriosis.

Does keeping or removing ovaries change the answer?

Keeping ovaries does not restore a removed uterine lining. Removing them before menopause can bring on menopausal symptoms immediately, which is a different issue from uterine protection. ACOG’s surgery guidance separates these operations; neither description alone diagnoses a progesterone deficiency.

The ovaries produce hormones; the uterine lining is a tissue that can respond to them. ACOG explains that ovarian removal is a separate surgical decision from hysterectomy. That difference matters when discussing the onset of menopausal symptoms and the purpose of hormone therapy, even though both procedures may have happened during one operation.

Another distinction is endometrial ablation, a treatment of the lining rather than removal of the uterus. The BMS protection guidance addresses it separately. Do not treat the absence of periods after a procedure as proof that the uterus is absent. Tell the prescriber which procedure was performed and allow the medical record to establish what that means for endometrial protection and any new bleeding.

Editorial illustration: an unbranded container, information sheet and magnifying glass.
Removing ovaries and treating the lining are different matters — keep the exact product identity and its complete label together.

Review symptoms and product identity without inferring eligibility

A person without a uterus can still have reasons why a particular hormone treatment is unsuitable. The FDA overview presents treatment categories alongside the need to consider medical history and the relevant labeling. Removing one endometrial question does not remove every cardiovascular, breast, clotting or other consideration, and a symptom list cannot establish an appropriate prescription.

Also identify whether the estrogen is systemic or intended as low-dose local therapy; our vaginal-product guide explains that difference. If bleeding occurs after surgery or menopause, report it for assessment rather than assuming it cannot matter without a uterus. Our unexpected-bleeding guide helps describe the event without assigning its cause.

Femring’s label illustrates why the product matters: estradiol is absorbed into the circulation from this vaginal ring, which is labeled for moderate-to-severe vasomotor symptoms and vulvar/vaginal atrophy. A vaginal route alone does not mean low-dose local therapy.

Ask the service to explain the reason, not merely confirm the request

When reading the CoreAge Rx review or care comparison, ask whether the clinician can review the surgery information and explain the purpose of each medicine. A questionnaire answer about hysterectomy may be a starting point, but unresolved details should not disappear because a purchase process offers a convenient next step.

CoreAge is commercially featured through The Uterus Question's participation in its promotional publishing network. That position does not settle the postoperative treatment question. A useful consultation leaves you understanding the general approach, any exception relevant to the actual history and who will reassess the plan. It should not leave you choosing between conflicting internet rules on your own.

The Duke Health review and MyMenopauseRx review offer two clinical-service contexts for preparing this conversation. Bring the question about the operative record to the relevant professional. Neither a service listing nor this guide can decide how an individual surgical history changes a prescription.

Can progesterone alone help symptoms after hysterectomy?

Progesterone alone for symptoms is a different question from protecting the lining during estrogen treatment. Our postmenopausal hot-flash trial analysis uses an abstract and does not establish a postoperative subgroup result. Our perimenopause trial analysis reports hysterectomy as an exclusion. Those October 2026 analyses explain the study populations and limitations; they do not establish symptom benefit specifically after hysterectomy. A study dose is not a postoperative prescription.

PROMETRIUM, 100 mg and stopping: what does the label establish?

The PROMETRIUM label lists endometrial-hyperplasia prevention for postmenopausal women with a uterus taking conjugated-estrogen tablets, and secondary amenorrhea. Its indication section does not list hot flashes or insomnia. This named product’s label does not establish equivalent uses for compounded formulations.

PROMETRIUM contains peanut oil and is contraindicated for peanut allergy. The label warns about dizziness and drowsiness and lists other contraindications, including unexplained genital bleeding, breast-cancer history, thromboembolic disease and liver disease. Hysterectomy does not remove those safety questions.

A 100 mg strength identifies the capsule. It does not establish a postoperative treatment plan. Decisions about starting, continuing or stopping also depend on the prescribing reason and your medical history.

Sources behind this article

Use the original documents to check their scope. A provider’s offer and a named medicine’s label establish different facts.

  1. DailyMed: Femring estradiol acetate vaginal ring, record updated December 9, 2025Exact product label; prescribing information revised November 2023 · Checked 2026-09-27
  2. ACOG: HysterectomySpecialty society surgery terminology and patient guidance · Checked 2026-09-27
  3. British Menopause Society: Progestogens and Endometrial Protection, May 2026UK specialty clinical guidance; evidence limits, not US product approval · Checked 2026-09-27
  4. British Menopause Society: Induced Menopause in Women with Endometriosis, February 2026UK specialty clinical guidance; limited evidence and individualized discussion · Checked 2026-09-27
  5. FDA: current hormone therapy categories and warning changesFederal regulator patient information · Checked 2026-09-27
  6. PROMETRIUM: February 2026 label revision; DailyMed record updated July 23, 2026U.S. product label · Checked 2026-11-13
  7. ACOG: Hysterectomy; updated and reviewed October 2026U.S. patient guidance · Checked 2026-11-13
  8. BMS: Progestogens and endometrial protection; May 2026 file, reviewed February 2026UK professional guidance · Checked 2026-11-13
  9. Femring: November 2023 label revision; DailyMed record updated October 29, 2026U.S. product label · Checked 2026-11-13
  10. Oral micronized progesterone for vasomotor symptoms--a placebo-controlled randomized trial in healthy postmenopausal women.Indexed primary study abstract · Checked 2026-10-21
  11. Oral micronized progesterone for perimenopausal night sweats and hot flushes a Phase III Canada-wide randomized placebo-controlled 4 month trial.Indexed primary study abstract and full research article · Checked 2026-10-21
Read our editorial method →